Although some trials have allowed matched or single HLA-antigen mismatched related donors (mmRD) along with HLA-matched sibling donors (MSD) for pediatric bone marrow transplantation (BMT) in early stage hematologic malignancies, whether mmRD grafts lead to similar outcomes is not known. We compared patients <18y reported to the CIBMTR with AML, ALL, CML and MDS undergoing allogeneic T-replete, myeloablative BMT between 1993 and 2006. In total, patients receiving bone marrow from 1208 MSD, 266 8/8 allelic matched unrelated donors (URD) and 151 0-1 HLA-antigen mmRD were studied. Multivariate analysis showed that recipients of MSD transplantation had less transplant related mortality (TRM) and acute and chronic GVHD, along with better disease-free (DFS) and overall survival (OS) compared with URD and mmRD groups. There were no differences in TRM, acute and chronic GVHD, relapse, DFS or OS between the mmRD and URD groups. These data show that mmRD and 8/8 URD outcomes are similar, while MSD outcomes are superior to the other two sources.
Introduction
The benchmark for the best survival of children undergoing myeloablative bone marrow transplant (BMT) for leukemia has been the results obtained with the use of HLAmatched sibling donors (MSD). This is conventionally referred to as a "6/6" match, i.e. a tissue type match at a low level of resolution at the Human Leukocyte Antigen (HLA) region at HLA-A and B and at the allelic level at DRB1. In the vast majority of related cases, this equates to a complete allelic match along both HLA haplotypes, together with the associated genes. Only 1/3 of patients have a MSD. Alternative donor types are critical for the remaining 2/3 of the population.
In the 1980s and early 1990s, when unrelated transplantation was not an option for most patients, attempts were made to use family donors who were less well matched than an HLA-identical sibling. This resulted in several protocols that offered transplant using a sibling donor with a single HLA antigen mis-match or a family donor with a zero or one HLA antigen mismatch (mismatched related donors, mmRD). Some studies suggested that survival rates achieved using these donors were similar to outcomes after MSD transplantation; this was on the basis of a higher risk of graft-versus-host disease (GVHD) being counterbalanced by a reduced risk of relapse, the two major adverse outcomes of allogeneic BMT for malignant diseases. [1] [2] [3] [4] These observations supported the practice of using mmRD in early stage-patients, similar to HLA-matched sibling donors. Over the past two decades, however, the indications for transplantation have been refined as results using chemotherapy have improved and risk groups have been defined with more precision. With this in mind, it is important to continually reFor personal use only. on September 14, 2017 . by guest www.bloodjournal.org From evaluate the risk-benefit ratio of subjecting patients to transplant, including different types of donors, compared with chemotherapy approaches.
Several retrospective pediatric studies have reported series of patients where the outcome is similar for recipients of MSD transplants and unrelated donor (URD) transplants. [4] [5] [6] [7] [8] [9] [10] Recent publications relating to the use of URD show a clear relationship between the level of HLA-allelic match and outcome.
11 ;12 In order to clarify data regarding choice of donors, we organized a study to re-evaluate the role of transplants using mmRD in the current era in a purely pediatric population and compare outcomes after BMT using a MSD or URD. This study compares the outcomes of BMT using one-antigen mismatched related donors (5/6 match) or phenotypically matched non-sibling related donors vs. MSD vs. HLA-A, B, C and DRB1 (8/8) allele matched URD in pediatric patients with leukemia and myelodysplasia.
Methods

Data collection
The Participating centers are required to report all transplants consecutively; compliance is monitored 
Study population
This study was restricted to pediatric patients (<18y) with AML, ALL, CML and MDS undergoing a first allogeneic transplantation from 1993-2006. In total, transplants using 1208 MSD, 97 one-antigen mismatched related, 54 phenotypically matched non-sibling related donors and 266 8/8 allele matched URD were included in the study. The inclusion and exclusion criteria are shown in detail in the Supplemental Table 1 .
In order to reduce heterogeneity in the study population, we limited the study to those patients who received myeloablative conditioning with bone marrow as the only source of cells.
Prophylaxis against GVHD was limited to calcineurin inhibitors, with or without methotrexate, and no ex-vivo T cell depletion was permitted.
Data on matched siblings were used only from institutions who also contributed transplant data for the mismatched related transplant group. Selection of the donor and care of the recipient, including prophylactic therapies, was per an institution's standards. The level of HLA mismatch for one-antigen mismatch and phenotypically matched related group was The unrelated donor group was restricted to a subset whose typing had been confirmed through the NMDP high resolution retrospective typing program as being an 8/8 allelic match at HLA-A, B, C and DRB1 with the patients. 13 All surviving unrelated recipients included in this analysis were retrospectively contacted and provided informed consent for participation in the NMDP research program. Approximately 9% of surviving patients would not provide consent for use of the research data. To adjust for the potential bias introduced by exclusion of nonconsenting surviving patients, a corrective action plan modeling process randomly excluded appropriately the same percentage of deceased patients using a biased coin randomization with exclusion probabilities based on characteristics associated with not providing consent for use of the data in survivors (CAP modeling). 12 Patient-, disease-, and transplant-related characteristics are listed in Table 1 .
Endpoints
The objective of this study was to compare the outcomes of BMT using a one-antigen mismatched related donor or phenotypically matched related donor vs. a MSD vs. an 8/8
matched URD in pediatric patients with malignant diseases. The main outcomes analyzed were treatment-related mortality (TRM), acute and chronic GVHD, relapse, disease-free survival (DFS) and overall survival (OS). The acute GVHD end-point referred to the development of grades 2-4 and grades 3-4 according to the Glucksberg criteria. 14 
Chronic GVHD was
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From diagnosed following the standard definitions. 15 Relapse consisted of leukemia relapse or MDS recurrence, whereas TRM was death resulting from any cause other than relapse. DFS was defined as survival in complete remission after BMT. For OS, death from any cause was considered an event. All living patients were censored at last follow-up.
Statistical analysis
An analysis was performed to look for differences in outcomes between the phenotypically matched and 1-antigen mismatched related donor groups. Because we were performing a large number of comparisons, p<0.01 was considered significant (See Table 3 ).
There were no statistically significant differences in major outcomes between these two donor groups and so they were combined together for the subsequent analysis. For consistency, this group will be referred to as the mismatched related group (mmRD). Frailty models were employed to test for center effects and no statistically significant evidence for center effects was found. Patient-, disease-, and transplant-related variables were compared between any two of the three groups (MSD, URD, mmRD) using the χ 2 statistic for categorical variables and the Kruskal-Wallis test for continuous variables. Occurrence of GVHD, TRM and disease relapse were calculated using cumulative incidence estimates, taking into account the competing risk. 16 Probabilities of DFS and OS were estimated from the time of transplantation using Kaplan-Meier For the multivariate analysis, Cox proportional hazards regression models were applied.
The proportional hazards assumption was assessed for each covariate by using a time-dependent covariate approach. Covariates which violated the proportional hazard assumption were adjusted by stratification. The interaction between the donor type and the other covariates was then checked. Stepwise forward-backward selection was used to build the models from the prognostic factors under consideration. Due to multiple comparisons included in the statistical analysis, a p<0.01 was defined as statistically significant. All p-values were two-sided. All analyses were performed using SAS 9.1 (SAS Institute, Cary, NC).
After completion of the main analysis, a sub-analysis was performed on that portion of the mmRD where typing was available at HLA C antigen. As these donors could be classified at 4 loci, these 8/8 parents or 7/8 siblings or parents are referred to as the mmRD subgroup.
Univariate and multivariate comparisons were performed as outlined above. Further analysis of patients by allele level typing was not possible, as only a small fraction (~2%) of the sample had been typed at the allele level.
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Results
Mismatched related donor group
The group of 151 mmRD included 43 siblings, 88 parents, 2 children and 18 other relatives (Table 1) . Fifty-four were a 6/6 match, meaning that the reviewed HLA report showed a low-resolution match at A, B and DRB1. Ninety-seven had a mismatch at one antigen; at the A locus in 48 cases, at B in 19 and at DRB1 in 30. Antigen level HLA C typing was available in approximately half of the cases; being reported in only 46% of donors used between [1993] [1994] [1995] [1996] [1997] [1998] [1999] and 61% between 2000-2006 (not statistically significant; chi square p=0.132). The small sample size precluded the analysis of locus-specific mismatch effects. Because the reported data rarely included allele-level typing, it was not possible to classify these donors by allele-level mismatches. In addition, pedigree data was not available to classify the mismatches as crossover events or as phenotype matches with different haplotypes. A comparison of the phenotypically matched group with the one-antigen mismatched group by multivariate analysis did not show statistically significant differences (Table 2 ). It should be noted that the relative risks in general favored the phenotypically matched donors over the one-antigen mismatched donors, but only the p-value for chronic GVHD approached, but did not exceed, our cut-off of 0.01 for significance. Given the similarity of outcomes of the phenotypically matched and one-antigen mismatched subsets, the groups were pooled as the mmRD group for the major analyses.
Patient, disease, and transplant characteristics
Details of the patient groups are shown in Table 1 . Patients receiving an URD transplant had more intermediate/advanced disease (71% vs. 50% for MSD vs. 55% for mmRD), and had a longer time from diagnosis to transplant with a median of 14 months compared to 7 months for MSD and 8 months for mmRD. Recipients of URD transplantation were more likely to be conditioned using total body irradiation (TBI) (80%) than the MSD (53%) or mmRD (57%) group. Of note, for the key characteristics mentioned above (advanced vs. early disease, time to BMT, TBI conditioning), along with other important characteristics (gender mismatches, CMV status), the mmRD most closely resembled the MSD group, suggesting a use pattern of mmRD similar to MSD by pediatric centers. The median follow-up for survivors was 79 months, 62 months, 61 months for MSD, mmRD and URD, respectively.
Graft versus Host Disease
Univariate analysis showed that the probability of grade 2-4 acute GVHD at 100 days in the MSD group was less than that in mmRD or URD group, with 29% (95% CI 26-31%), 56% (95% CI 48-64%), and 45%(95% CI 39-51%) respectively (Table 3) . Similarly, the rate of grade 3-4 acute GVHD at 100 days was less in MSD group with 10% (95% CI 8-11%), compared to 26% (95% CI 20-34%) in mmRD group, and 18% (95% CI 14-23%) in URD group ( Figure 1A ).
Chronic GVHD at 1 year was 15% (95% CI 13-17%) for MSD, half that of the 30% (95%CI 23-38%) for mmRD or 33% (95% CI 27-39%) for URD ( Figure 1B) . Extensive chronic GVHD at 1 year was 6% (95% CI 5-7%) for MSD, significantly less than the 13% (95%CI 8-19%) for mmRD or 21% (95% CI 17-27%) for URD (Table 3) .
Multivariate analysis confirmed lower rates of GVHD in MSD recipients. Patients transplanted using a MSD had lower risks of grades 2-4 and 3-4 acute GVHD and chronic GVHD than the mmRD or URD groups (all p<0.001) ( Table 4) . URD recipients had a significantly lower risk of acute GVHD grades 2-4 compared to mmRD (RR 0.65, 95% CI 0.49-0.86, p=0.003), but differences in grades 3-4 acute GVHD or chronic GVHD between mmRD and URD were not significant.
Relapse
The cumulative incidence of relapse at 3 years was 36% (95%CI 33-39%) after MSD transplant, compared to 29% (95%CI 22-37%) for mmRD and 32% (95% 27-38%) for the URD group ( Table 3) . The trend toward a lower relapse rate after mmRD transplant compared to MSD transplant in univariate analysis (Table 3) was not supported by the multivariate analysis, which adjusted for TBI use and year of transplant, and stratified by performance score, disease, disease status, and time from diagnosis to transplant (Table 4) .
Treatment-related mortality
The cumulative incidence of TRM at 3 years was 10% (95% CI 8-12%) for the MSD group, compared to 27% (95% CI 20-34%) for the mmRD group and 24% (95% CI 19-30%) for the URD group (Table 3, Figure 1C ). Table 4 shows the results of the multivariate analysis for TRM. The rate of TRM for MSD group was significantly less than the other two groups (both p<0.001). However, no difference was found between the use of mmRD or URD (RR 1. 16 
Disease-free survival
Unadjusted disease-free survival rates at 3 years were 54% (95% CI 51-57%), 44% (95% CI 36-53%), and 43% (95% CI 37-49%) for MSD, mmRD, and URD transplants respectively (Table 3) . Of note, while mmRD recipients had disease risk profiles similar to MSD recipients, mmRD unadjusted DFS tracks more closely with the outcomes of URD recipients, who as a group have higher disease risk. This observation is confirmed with multivariate analysis, which showed that transplants using MSD resulted in superior DFS when compared to mmRD (RR 0.72, 95% CI 0.57-0.92, p=0.008) or URD transplant (RR 0.71, 95% CI 0.59-0.86, p=0.001). However, no difference was detected between URD and mmRD (RR 1.02, 95% CI 0.77-1.35, p=0.904, Table 4 ).
Overall survival
Unadjusted overall survival was 61% (95% CI 58-64%), 51% (95% CI 43-60%), 50% (95% CI 44-56%) at 3 years for MSD, mmRD, and URD transplants respectively (Table 3 ). In Table 4 multivariate analysis shows a lower survival rate with mmRD than MSD (RR 1.55, 95% CI 1.21-1.98, p<0.001, Table 4 
Discussion
Although transplantation using an HLA-matched sibling donor (MSD) provides the best outcome for patients with malignant disease, at most, one third of patients will have such a donor available and the remaining 2/3 of the population will require an alternative donor type.
Within this large registry study of pediatric recipients of related and unrelated BMT, we observed that recipients of transplants using MSD grafts have superior outcomes compared to recipients of mmRD or URD grafts. The data also show that outcomes in recipients receiving 8/8 allelic matched URD produce overall outcomes similar to recipients of mmRD. We limited our analysis to conditions for which pediatric BMT continues to use ablative conditioning regimens without ex-vivo T cell depletion in the large majority of cases. Therefore, the groups we analyzed were relatively homogeneous according to indications, preparative regimens, and GVHD prophylaxis and reflect current clinical practice. The data were insufficient to explore differences between types of phenotypic or allelic mismatches within the mmRD group, as only a small number of the mmRD had allele-level typing available. A sub-analysis suggested that the parental donors who were matched at the 8/8 antigens, and sibling or parent donors who matched at 7/8 antigens persisted in sharing a clinical course comparable to the 8/8 URD group (similar rates of GVHD and TRM, DFS and OS), but their DFS and OS was not significantly different from the MSD group. This subanalysis can only hint that 7/8 or 8/8 mmRD may have equivalent survival to a MSD, as there are too few patients in this subgroup to definitively show this improvement in survival. This is shown by the broad confidence intervals and lack of statistical significance in the 3yr OS rates between the mmRD subgroup and both the 8/8 URD and MSD groups. These findings are significant because they call into question the current practice in pediatric transplantation of using a mmRD interchangeably with a MSD.
The study is limited by its retrospective nature and the fact that we do not know the clinical decision making behind any individual BMT. Recipients of 8/8 URD transplants had more intermediate/advanced disease, and a longer interval from diagnosis to transplant than the mmRD and MSD groups (Table 1 ). This observation suggests that treating clinicians considered a mmRD in the same manner and at the same time as a MSD rather than URD, particularly as the centers contributing the MSD were restricted to centers that also contributed to the mmRD group. Because the mmRD recipient population more closely resembled the risk profile of the MSD group compared to the higher risk 8/8 URD recipient population, it makes this finding even more striking and adds to the validity of our conclusion. Our analysis suggests that a mmRD should be considered equivalent to an 8/8 matched URD, not to a MSD.
One of the original papers describing the use of mmRD found comparable outcome for MSD and 0-1 locus mismatched donors. 1 However, for these patients, transplanted between 1975 and 1986 with single agent methotrexate as GvHD prophylaxis, the outcome for their early- report in a primarily adult population compared the outcome for patients with leukemia transplanted using MSD, mmRD or URD and found superior outcomes for MSD compared to all alternative donor types. 18 Direct comparisons between 1-antigen mmRD and matched unrelated donors found no statistically significant difference in TRM, with outcomes for both inferior to MSD. T-cell depletion was used in 49% of the mmRD transplants in this series (Szydlo et al),
but similar findings were still seen in a large Japanese study of adult patients, all T replete. 19 While there are marked differences in the age of the study populations across the three studies, and the use of T cell depletion in Szydlo et al, the overall effects of donor source on outcome are consistent.
There are no previous studies with numbers sufficient to address this issue in a pediatric recipient population. In AML, Neudorf et al concluded that patients who received grafts from a one-antigen-mismatched donor had a DFS which was not statistically different from DFS for patients who received HLA-identical grafts, but the conclusion was based on only 6 patients. 4 In a high-risk ALL BFM study, transplant was scheduled to occur if there was a MSD or a "compatible" related donor. The inclusion criteria for such a donor was a 0 to 1 locus mismatch at 4 loci (antigen at A, B, C; allele at DRB1), i.e. a minimum of 7/8 match, rather than potentially a 6/8 match. Of the 77 with a compatible donor, 76 were siblings and only one was a compatible related donor. 20 Thus, even large, multicentre, prospective studies recruit too few mmRD recipients to allow a precise assessment of outcome using related alternative donors.
Although our sub-analysis of 54 donors with HLA-C typing available suggests that inclusion of these 0 to 1 locus out of 8 antigen mismatches may produce long term survival similar to MSD, there are insufficient numbers in this group to show an improvement in survival compared to One of the traditional factors that drove the use of mismatched donors was the concept that the mismatch generated more graft versus leukemia, which counteracted an increase in TRM due to GVHD. In our study, the relapse rate was not statistically different between the three donor groups, even controlling for disease status. Also, within the comparison of the phenotypically matched related versus the one antigen mismatch group, there was no significant difference in relapse rates. Previous studies allowed a greater degree of mismatch and it could be that our better matching means that the difference in relapse rate is less. This is consistent with recent publications; a CIBMTR study published in 2009 did not find an improved graftversus-leukemia effect with 8/8 allelic matched URD compared with MSD, and reported comparable rates of grade 3-4 acute GVHD in the URD and MSD groups. 21 The original intent of this study was to look in depth at the mmRD group, and reclassify those who were a 0-1 antigen mismatched at low resolution into 0,1,2,3 out of 8 mismatches at the allelic level. However, detailed typing was not available in sufficient numbers of patients to permit the allelic level analysis to proceed (<2% of donors has allelic typing), showing that the large majority of the pediatric BMT community submitting data to the CIBMTR do not feel allele-level typing is necessary in mmRD. The relationship between degree of mismatch at the allele level and outcome remains an important one. The small improvement in survival we noted when analyzing the mmRD cohorts with 7/8 and 8/8 antigen level typing suggests that better typing may lead to better outcomes, but larger numbers are needed to prove this assertion. We urge the pediatric BMT community to change their clinical practice to include allele-level HLA For personal use only. on September 14, 2017. by guest www.bloodjournal.org From typing of all mmRD obtain and report typing at the allele-level to registries so that this analysis can be performed.
Our data supports the use of an mmRD as an acceptable alternative to an 8/8 allelic matched URD. Depending on local circumstances, it may be faster to identify a family donor, particularly if one can predict that an unrelated search is less likely to produce an 8/8 allelic match. In certain areas of the world, having large extended families and lacking access to unrelated donors may also favor use of a mmRD. 22 For pediatric patients with leukemia, if an 8/8 URD is not available, a well-matched cord blood unit with a good cell dose will produce results comparable to an allelic matched unrelated donor. 23 A cord blood search may also be faster than an extended family search, and cord blood is a cell source that will be considered in future comparative studies.
In summary, use of a 0 or 1 antigen mmRD results in outcomes similar to the use of an allelic 8/8 matched URD. Both have toxicities and complications that are higher than when a MSD is used. If a mmRD is used, the likely clinical course post-BMT mirrors that of an unrelated transplant rather than a MSD transplant, and this should be the basis of the information and consent process for the family of the patient. Whether more data and further analysis of allele level mismatches will allow us to identify a sub-group of the mmRD cohort that mirrors a MSD transplant rather than an URD transplant remains to be seen. *Early disease is defined as patients with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) in first complete remission, chronic myeloid leukemia (CML) in first chronic phase and myelodysplasia with refractory anemia or acquired idiopathic sideroblastic anemia.
Intermediate is defined as ALL and AML in second or greater complete remission, CML in accelerated phase or second or greater chronic phase; and advanced is defined as primary induction failure of ALL and AML, blastic phase of CML, relapse, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, chronic myelomonocytic leukemia and Juvenile myelomonocytic leukemia. * Adjusted for TBI use, and stratified by GVHD prophylaxis. † Adjusted for year of transplant, and stratified by GVHD prophylaxis. ‡ Adjusted for donor-recipient gender match, performance score, recipient age at transplant, GVHD prophylaxis and ATG use. § Adjusted for recipient age at transplant, performance score, disease, donor-recipient gender match, and year of transplant. | | Adjusted for TBI use in conditioning and year of transplant, and stratified by performance score, disease, disease status, time from diagnosis to transplant. ¶ Adjusted for donor-recipient CMV match and recipient age at transplant, and stratified by disease and disease status. # Adjusted for disease, disease status, recipient age at transplant, and stratified by performance score, use of ATG in conditioning, and years of transplant.
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